Navigation

TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: costing statement

A costing statement has been produced because the national resource impact is not considered to be significant because either the drug is not recommended for use or is one of a number of options which are comparatively priced.

The statement has been prepared in consultation with the manufacturer and experts working in this area and has been approved for publication by NICE.

Disclaimer
This resource is an implementation tool and should be used alongside the published guidance. The information does not supersede or replace the guidance itself.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk

This page was last updated: 17 June 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.